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Recently, we cloned two Na+-coupled lactate transporters from mouse kidney, a high-affinity transporter (SMCT1 or slc5a8) and a low-affinity
transporter (SMCT2 or slc5a12). Here we report on the cloning and functional characterization of human SMCT2 (SLC5A12) and compare the
immunolocalization patterns of slc5a12 and slc5a8 in mouse kidney. The human SMCT2 cDNA codes for a protein consisting of 618 amino acids.
When expressed in mammalian cells or Xenopus oocytes, human SMCT2 mediates Na+-coupled transport of lactate, pyruvate and nicotinate. The
affinities of the transporter for these substrates are lower than those reported for human SMCT1. Several non-steroidal anti-inflammatory drugs
inhibit human SMCT2-mediated nicotinate transport, suggesting that NSAIDs interact with the transporter as they do with human SMCT1.
Immunofluorescence microscopy of mouse kidney sections with an antibody specific for SMCT2 shows that the transporter is expressed
predominantly in the cortex. Similar studies with an anti-SMCT1 antibody demonstrate that SMCT1 is also expressed mostly in the cortex. Dual-
labeling of SMCT1 and SMCT2 with 4F2hc (CD98), a marker for basolateral membrane of proximal tubular cells in the S1 and S2 segments of
the nephron, shows that both SMCT1 and SMCT2 are expressed in the apical membrane of the tubular cells. These studies also show that while
SMCT2 is broadly expressed along the entire length of the proximal tubule (S1/S2/S3 segments), the expression of SMCT1 is mostly limited to
the S3 segment. These studies suggest that the low-affinity transporter SMCT2 initiates lactate absorption in the early parts of the proximal tubule
followed by the participation of the high-affinity transporter SMCT1 in the latter parts of the proximal tubule.
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Normal blood lactate levels are ∼1.5 mM, but less than 5%
of filtered lactate is excreted in the urine, suggesting the
presence of efficient mechanisms for reabsorption of lactate in
the kidney [1,2]. While Na+-independent, H+-coupled mono-
carboxylate transporters (MCTs) are known to play a major role
in the transmembrane transfer of lactate in a variety of cells [3],
lactate uptake in renal apical membrane vesicles occurs via Na+-
dependent processes [4,5]. Jorgensen and Sheikh, using apical⁎ Corresponding author. Tel.: +1 706 721 1761; fax: +1 706 721 3891.
E-mail address: pprasad@mail.mcg.edu (P.D. Prasad).
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doi:10.1016/j.bbamem.2007.06.031membrane vesicles isolated from the outer and inner layers of
rabbit kidney cortex, have provided evidence for the presence of
two Na+-dependent transport systems for monocarboxylates in
the proximal tubule [6–9]. A low-affinity Na+-coupled lactate
transport system (Km ∼40 mM) is expressed in the initial part
(pars convoluta) of the proximal tubule and a high-affinity Na+-
coupled lactate transport system (Km ∼0.25 mM) is expressed
in the distal part (pars recta) of the proximal tubule [6].
The molecular identity of the high-affinity lactate transport
system was recently revealed with the functional characterization
of SLC5A8, also known as SMCT1 (Sodium-coupled Mono
Carboxylate Transporter 1) [10–14]. SMCT1 transports lactate,
pyruvate, butyrate, propionate, acetate and the B-complex
vitamin nicotinate in a Na+-coupled and electrogenic manner.
The Km for SLC5A8-mediated lactate transport is ∼0.25 mM,
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lactate transport system in apical membrane vesicles from pars
recta. More recently, we cloned slc5a12 (SMCT2) from a mouse
kidney cDNA library and characterized its transport function [15].
The mouse slc5a12 is structurally and functionally similar to
mouse slc5a8. The two proteins share 59% identity and 75%
similarity at the amino acid level. Functionally, slc5a12 mediates
the transport of various monocarboxylates with low affinity (Km
for lactate,∼35mM), which agrees well with the values obtained
for the low-affinity lactate transport system in apical membrane
vesicles from pars convoluta. The mouse slc5a12-mediated
transport process was Na+-dependent and weakly electrogenic.
Recently, we provided evidence for the obligatory nature of these
two transporters in renal reabsorption of lactate in a mouse model
(c/ebpδ null mice) which lack the expression of both transporters
in kidney [16].
In this paper, we report on the cloning and functional
characterization of human SMCT2. In addition, we have com-
pared the expression patterns of SMCT1 and SMCT2 in mouse
kidney. These studies show that human SMCT2 functions as a
low-affinity Na+-coupled transporter for monocarboxylates and
that the transporter is indeed expressed in the apical membrane of
the cells lining the initial segments of the proximal tubule. In
contrast, the high-affinity Na+-coupled lactate transporter SMCT1
is expressed in the apical membrane of the cells lining the late
segments of the proximal tubule.
2. Materials and methods
2.1. Cloning of the human SMCT2
Since there was no sequence information for human SMCT2 cDNA in
GenBank, we first performed a Translated Blast (TBLASTN) search against the
human genome database using the amino acid sequence of mouse SMCT2 as the
query. The search identified a candidate gene for SMCT2 on human chromosome
11 (GenBank accession number NT_009237). Based on the predicted exons of the
gene, sense and antisense primers were designed to clone the full-length human
SMCT2 cDNA by RT-PCR using human kidney total RNA (Clontech). The sense
primer, containing the initiation codon (shown in bold) and an artificial Kozak
sequence (underlined), was 5′-GATATATAGCCATGGAGGTGAAGAACTTTG-
3′, and the antisense primer, located immediately downstream of the stop codon,
was 5′-CGTCTAGATGTGCATTCATACAGGTATTG-3′. Engineered into the 5′-
end of the antisense primer is an XbaI site (underlined), added to aid in the
directional cloning of the amplified cDNA. The ∼1.8-kb-long amplification
product obtained was cloned into pcDNA3.1 (Invitrogen) and pGH19 (kindly
provided by Dr. Peter S. Aronson, Yale University) vectors such that the sense
transcription of the cloned insert was under the control of T7 promoter. The identity
of the cloned cDNAwas confirmed by nucleotide sequencing.
2.2. Functional analysis of human SMCT2 in mammalian cells
This was done using the vaccinia virus expression system with human retinal
pigment epithelial (HRPE) cells as described previously [13,15]. Uptake of L-[14C]
lactate, [14C]nicotinate (both from American Radiolabeled Chemicals), and [14C]
pyruvate (Moravek Biochemicals) was measured in HRPE cells transfected with
the cloned cDNA 15 h following transfection. The uptake medium contained
25 mM HEPES/Tris (pH 7.5), 140 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2,
0.8 mMMgSO4, and 5 mM glucose. When transport measurements were made in
the absence of Na+, NaCl in the uptake buffer was replaced with an equimolar
concentration ofN-methyl-D-glucamine (NMDG) chloride. Dose–response studies
in which high concentrations of substrates as sodium salts were used, the
concentration of NaCl in the uptake buffer was held constant at 100 mM andosmolarity maintained by the addition of appropriate concentrations of sodium
gluconate. Endogenous uptake was measured in parallel using cells transfected
with empty vector and subtracted from the corresponding uptake values measured
in cells transfected with human SMCT2 cDNA to determine the cDNA-specific
uptake. Uptake measurements were made in triplicate and experiments were
repeated at least three times. Results are presented as means±S.E.M. of these
replicates. Statistical significance was analyzed by Student's t test.
2.3. Functional analysis of human SMCT2 in Xenopus laevis oocytes
Capped cRNA from human SMCT2 cDNA cloned in the pGH19 oocyte
expression vector was synthesized using the mMESSAGE mMACHINE kit
(Ambion). Mature oocytes from X. laeviswere injected with 50 ng of cRNA and
were used for uptake on the 5th day. Oocytes injected with water served as
control. Uptake of radiolabeled substrates in control and SMCT2-expressing
oocytes was determined as described previously [17]. Groups of 8–10 oocytes
were incubated with 25 μM [14C]nicotinate for 1 h at room temperature in NaCl-
containing uptake buffer (100 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1 mM
CaCl2, 3 mM HEPES, 3 mM Mes, and 3 mM Tris, pH 7.5). At the end of 1 h,
uptake was stopped by washing the oocytes 5 times with ice-cold uptake buffer.
Subsequently, the oocytes were individually transferred to scintillation vials and
lysed in 100 μl of 1% SDS/0.2 N NaOH and the radioactivity associated with
each oocyte determined by liquid scintillation spectrometry. When the effect of
the cation on the uptake was investigated, the NaCl in the uptake buffer was
replaced with equimolar amounts of either KCl, LiCl, choline chloride or
NMDG chloride. The Na+-activation kinetics was analyzed by measuring
human SMCT2-specific nicotinate uptake in the presence of increasing
concentrations of Na+. The data were analyzed by the Hill equation to determine
the Hill coefficient (h; the number of Na+ ions involved in the activation
process). The kinetic parameters were determined using the computer software
Sigma Plot, version 8.0 (Systat Software, Inc.) and the statistical significance of
the data determined by Student's t test.
2.4. Generation of polyclonal antibody against SMCT2
A rabbit polyclonal anti-peptide antibody against mouse SMCT2 was raised by
immunizing rabbits with the KLH-conjugated synthetic peptide GVQHDRETEQ-
DYLD, which corresponds to amino acids 560–573 of mouse SMCT2. The
antiserum obtained was affinity purified by passing through a NHS-activated HP
column (Amersham Biosciences, Piscataway, NJ) in which the SMCT2-specific
antigenic peptide used for immunization was coupled to NHS-activated sepharose.
The specificity of the anti-SMCT2 antibody was confirmed by immunofluorescence
in HRPE cells following heterologous expression of mouse and human SMCT2
cDNAsby vaccinia virus-mediated expression.Cells transfectedwith pcDNA3.1 and
mouse SMCT1 were used as the negative controls. Twelve hours after transfection,
cells were fixed with 4% paraformaldehyde and incubated with the primary antibody
at 1:2000 dilution for 3 h at room temperature. Cells were subsequently washed with
PBS and then incubated for 45 min at room temperature with Alexa Fluor 568-
conjugated goat anti-rabbit secondary antibody. Cells were again washed, covered
with Vectashield and coverslipped, and analyzed under a fluorescence microscope.
2.5. Immunolocalization of SMCT2 and SMCT1 in mouse kidney
Regional expression of SMCT2 and SMCT1 proteins in the mouse kidney
was analyzed by immunofluorescence. The generation and specificity of rabbit
polyclonal antibody against mouse SMCT1 has already been reported [18]. The
fixation of mouse kidneys was performed as described by Bacic et al. [19]. Male
C57BL6/J mice were anesthetized with ketamine and xylazine and subsequently
fixed by vascular perfusion through the abdominal aorta. The fixative used for
perfusion contained 3% paraformaldehyde, 0.5% picric acid, 0.01% glutardial-
dehyde in a 3:2 mixture of 0.1 M cacodylate buffer (pH 7.4, adjusted to
300 mosm with sucrose) and 4% hydroxyl ethyl starch (HES; Fresenius Kabi
AG, Bad Homburg, Germany) in 0.9% NaCl. After 5 min, the fixative was
washed out by perfusion with cacodylate/sucrose buffer for 5 min. Kidneys were
removed and cut transversely into 2 mm slices which were subsequently
mounted on thin cork plates. The slices were then frozen in liquid propane and
stored at −80 °C until further use.
Fig. 1. (A) Comparison of the amino acid sequences of human SLC5A12 with that of mouse slc5a12. Identical amino acids are shaded dark and conservative substitutions
are shaded light. (B) Exon–intron organization of human SLC5A12 gene. Black boxes numbered 1–15 represent the exons and the shaded regions represent the introns.
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(CM1850, Leica, Wetzlar, Germany) and mounted on polylysine-coated
microscope slides (O.Kindler, Freiburg, Germany). The cryosections were cut
and dried at −20 °C for at least 12 h. When performing immunohistochemistry,
the sections were rehydrated in phosphate-buffered saline (PBS) for 20 min
before treating them for 3 min with 1% SDS in PBS. Following this antigen
retrieval, the tissue was washed three times in PBS for 5 min each. For blocking
nonspecific binding sites, the slides were incubated for 15 min with 1% bovine
serum albumin (Sigma-Aldrich GmbH, Buchs, Switzerland) dissolved in PBS/
0.02% sodium azide. The blocking solution was then carefully taken off and
substituted by the primary antibodies which were diluted in PBS/0.02% sodium
azide. Rabbit anti-SMCT2 and anti-SMCT1 antibodies were diluted 1:1000 and
1:4000, respectively. Goat anti-4F2hc (CD98) (Santa Cruz Biotechnologies,
CA, USA) antibodies were applied at 1:400. Incubation time of the primary
antibodies was 75 min, after which the slides were washed twice in hypertonic
PBS and once in PBS for 5 min each. After washing, the secondary antibodies
donkey anti-rabbit Alexa 594 (1:1000) and donkey anti-goat Alexa 488 (1:400)
(Molecular Probes, OR, USA) were applied at room temperature and incubated
for 1 h in the dark. Subsequent washing was performed as described before [19].
After final washing, the sections were mounted with Vectashield mounting
medium (Vector Laboratories, Burlingame, CA, USA) and subsequently stored
in the dark at 4 °C. Microscopic images were taken using a Leica SP1 UV
CLSM confocal microscope (Leica, Wetzlar, Germany) and pictures were
processed with Photoshop 7.0 software (Adobe, San Jose, CA).
3. Results
3.1. Structural features of the human SMCT2 cDNA and gene
The human SMCT2 cDNA, amplified by RT-PCR using human
kidney mRNA, was 1880 bp long and codes for a protein of 618amino acids. During the preparation of this manuscript, two
sequences for human SMCT2 with the accession numbers
NM_001042366 and AY299482 have been annotated in the
GenBank™ database. The nucleotide and the amino acid sequences
of human SMCT2 that we cloned are identical to the sequences
reported in the two submissions to GenBank™. Comparison of the
amino acid sequence between human SMCT2 and mouse SMCT2
(Fig. 1A) shows that the protein is highly conserved (85% identity
and 92% similarity) between the two species. SMCT2 shares
significant amino acid sequence homology with other members of
the SLC5 gene family, especially SMCT1 (SLC5A8) (57% identity
and 73% similarity) and NIS (SLC5A5) (48% identity and 66%
similarity). A comparison of the nucleotide sequence of the
genomic sequence entry NT_009237 in the GenBank™ database
and the nucleotide sequence of the open reading frame of human
SMCT2 cDNA indicated that the SLC5A12 gene is ∼50 kbp long
and consists of 15 exons and 14 introns. The SLC5A12 gene is
mapped to chromosome 11p14.2 and the exon–intron organization
of the gene is presented in Fig. 1B.
3.2. Functional features of human SMCT2 using a mammalian
cell expression system
We expressed the cDNA in HRPE cells using the vaccinia
virus expression technique and compared the uptake of lactate and
pyruvate (Fig. 2A) and nicotinate (Fig. 2B) in cDNA-transfected
cells with the uptake in cells transfectedwith the vector alone. The
Fig. 2. Functional expression of human SMCT2 (SLC5A12) in HRPE cells.
HRPE cells were transfected with either pcDNA3.1 vector alone (open bars) or
human SMCT2 cDNA (closed bars). (A, B) Uptake of [14C]lactate (500 μM),
[14C]pyruvate (500 μM), and [14C]nicotinate (30 μM) was measured in the
presence of Na+. (C) Uptake of [14C]nicotinate was measured either in control
buffer (25 mM HEPES/Tris, pH 7.5, 5.4 mM KCl, 1.8 mM CaCl2, 0.8 mM
MgSO4, 5 mM glucose, and 140 mM NaCl) or in buffer in which NaCl was
replaced with 140 mM of KCl or LiCl. Where indicated, uptake measured in
cDNA-transfected cells was significantly different from the corresponding
uptake measured in vector-transfected cells (⁎Pb0.05; ⁎⁎Pb0.01).
Fig. 3. Dose–response relationship for the inhibition of human SMCT2-mediated
[14C]nicotinate uptake by unlabeled nicotinate, lactate, and butyrate (A) and
inhibition of human SMCT2-mediated nicotinate uptake by NSAIDs (B). Human
SMCT2 cDNA was expressed in HRPE cells. Cells transfected with pcDNA3.1
vector served to determine endogenous transport. Uptake of [14C]nicotinate
(30μM)wasmeasured inNa+-containing buffer either in the presence of increasing
concentrations of unlabelled nicotinate, L-lactate, or butyrate (A) or various
NSAIDs (200μM) (B). Uptakemeasured in cells transfectedwith vector alonewas
subtracted from corresponding uptake measured in cells transfected with cDNA to
calculate cDNA-specific uptake. Results are expressed as percentage of control
uptake (100%) measured in the absence of inhibitors. The degree of statistical
significance for nicotinate uptake measured in the presence of various NSAIDs
compared to nicotinate uptake measured in the absence of NSAIDs in hSMCT2
cDNA-transfected cells is indicated by ⁎Pb0.05 and ⁎⁎Pb0.01.
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∼30% (Pb0.05), and ∼200% (Pb0.01) higher, respectively, in
cells expressing the cloned cDNA than in vector-transfected cells.
Subsequent characterization of the cloned cDNAwas done using
radiolabeled nicotinate as the tracer. Uptake of nicotinate was
measured in HRPE cells expressing human SMCT2 cDNA using
uptake buffers in which NaCl was substituted with equimolar
amounts of KCl or LiCl (Fig. 2C). Replacement of Na+ in the
uptake buffer with either K+ or Li+ almost completely abolished
nicotinate uptake mediated by human SMCT2, indicating the
obligatory nature of Na+ as the coupling ion for human SMCT2.
Substrate affinities for human SMCT2 were determined by
assessing the ability of unlabeled nicotinate, lactate and butyrate to
inhibit the transport of [14C]nicotinate in vector-transfected and
human SMCT2 cDNA-transfected HRPE cells (Fig. 3A). In these
experiments, the cDNA-specific uptake was calculated by
subtracting the transport measured in vector-transfected cells and
the IC50 values for nicotinate, lactate and butyratewere determined.
The values were found to be in the following order: butyrate (2.6±
0.4 mM)Nnicotinate (3.7±0.6 mM)N lactate (16.9±3.7 mM).
Previous studies from our laboratory have shown that non-
steroidal anti-inflammatory drugs (NSAIDs) interact with humanSMCT1 [20]. These studies have shown that NSAIDs are
inhibitors, not transportable substrates, of human SMCT1. To
investigate the interaction of NSAIDs with human SMCT2, we
monitored the effects of some representative NSAIDs (200 μM)
on human SMCT2-mediated [14C]nicotinate transport. As seen in
Fig. 3B, all NSAIDs tested inhibited human SMCT2-mediated
nicotinate transport, suggesting that these drugs interacted with
the transporter. The extent of inhibition, however, varied among
the different drugs. Fenoprofen and ibuprofen showed similar
extent of inhibition (54±3 and 49±4%, respectively; Pb0.01).
Inhibition by ketoprofen was the least (15±3%, Pb0.05).
3.3. Functional features of human SMCT2 using the X. laevis
oocyte expression system
Since the human SMCT2-mediated transport activity follow-
ing expression in HRPE cells was low, we explored the use of the
X. laevis oocyte expression system. We first measured the uptake
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the presence and absence of NaCl in the uptake buffer and
compared it with the uptake measured in water-injected oocytes
(Fig. 4A). Nicotinate uptake in human SMCT2 cRNA-injected
oocytes was∼20 fold higher compared to water-injected oocytes.
When NaCl in the buffer was substituted with chloride salt of K,
Li, NMDG, or choline, nicotinate uptake decreased drastically
and there was no significant difference in nicotinate uptake
measured between cRNA-injected oocytes and water-injected
oocytes. The uptake of [14C]nicotinate was completely inhibited
by unlabeled nicotinate, lactate and butyrate (data not shown),
suggesting that the uptake observed is specific and saturable and
that human SMCT2 can interact with short-chainmonocarboxylic
acids. When the uptake of nicotinate was measured in the
presence of the NSAIDs ibuprofen, fenoprofen and ketoprofen
(200 μM), human SMCT2-mediated nicotinate uptake into
cRNA-injected oocytes was significantly inhibited (Fig. 4B).
The extent of inhibition wasc 76±1% with ibuprofen, 67±3%
with fenoprofen and 45±6% with ketoprofen (Pb0.01 in all
cases). Themagnitude of inhibition obtainedwas relatively higher
in the oocyte system, compared to the mammalian expression
system (Fig. 3B). While the exact reason for the observed
difference is difficult to predict, it is quite possible that the
difference may be due to the differences in the various post-
translational modifications the protein is subjected to in the two
expression systems. The amino acid sequence of human SMCT2,
in addition to putative N-linked glycosylation sites, also has
several putative sites for phosphorylation and myristylation. Such
post-translational modifications can affect the interaction of a
transporter with its substrates/inhibitors. We next determined the
Na+-activation kinetics of human SMCT2-specific nicotinate
uptake by measuring the uptake in the presence of increasing
concentrations ofNa+ (0–100mM). The concentration ofCl−was
kept constant at 100 mM. The relationship between uptake and
Na+ concentration was weakly sigmoidal (Fig. 4C). The value forFig. 4. Characterization of human SMCT2-mediated transport process
in Xenopus oocytes. Oocytes were injected with either human SMCT2 cRNA
or water and used for the measurements of [14C]nicotinate (25 μM) uptake on
the 5th day. Uptake measured under identical conditions in water-injected
oocytes was subtracted from uptake in cRNA-injected oocytes to calculate
human SMCT2-specific uptake. (A) Cation specificity of human SMCT2-
mediated transport. Uptake was measured in control buffer (100 mM NaCl,
2 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 3 mM HEPES, 3 mM Mes, and 3 mM
Tris, pH 7.5) or in buffer in which NaCl was replaced with 100 mM of KCl,
LiCl, choline chloride or NMDG chloride. The degree of statistical significance
for uptake measured in cRNA-injected oocytes compared to water-injected
oocytes is indicated by ⁎Pb0.01. (B) Influence of NSAIDs on human SMCT2-
mediated nicotinate uptake. Uptake of [14C]nicotinate was measured in the
absence (control) or presence of 200 μM of various NSAIDs. Uptake
measurements were made in a medium containing 100 mM Na+. The degree
of statistical significance for nicotinate uptake measured in the presence of
various NSAIDs compared to nicotinate uptake measured in the absence of
NSAIDs in hSMCT2 cRNA-injected oocytes is indicated by ⁎Pb0.01. (C) Na+-
activation kinetics for human SMCT2-mediated nicotinate uptake. Uptake of
nicotinate was measured in the presence of increasing concentrations of Na+ (0–
100 mM). Concentration of Cl− was kept constant at 100 mM. Na+-dependent
uptake was calculated by subtracting the uptake measured in the absence of Na+
from the uptake measured in the presence of Na+. Data for the Na+-dependent
uptake were used in the analysis. Inset, Hill plot of the same data.the Hill coefficient (h) was slightly greater than 1 (1.4±0.2)which
was confirmed by the linear transformation of the data using the
Hill plot (Fig. 4C, inset). However, electrophysiological studies
with human SMCT2-expressing oocytes showed that the
transport process was associated with barely detectable inward
currents (b5 nA) in the presence of various substrates (data not
shown).
3.4. Immunofluorescence localization of SMCT2 and SMCT1
To determine the regional and subcellular distribution of
SMCT2 in kidney, we performed immunofluorescence analysis
in mouse kidney sections. The anti-peptide antibody raised
Fig. 5. Immunolocalization of SMCT2 and SMCT1 in mouse kidney. Consecutive cryosections of mouse kidney were stained with rabbit polyclonal antibodies
specific for SMCT2 or SMCT1 (red) together with an anti-4F2hc (CD98) antibody (green). Panels A and C: cortical sections (original magnification 200×),
demonstrating strong staining for SMCT2 and SMCT1 in different segments of the proximal tubule. Panels B and D: high magnification confocal laser microscope
images (original magnification 630×), showing localization of SMCT2 and SMCT1 in the brush border membrane of the proximal tubule. (B) SMCT2 staining was
observed along the entire proximal tubule localizing not only to the CD98-positive segments (S1 and S2) but also to the CD98-negative segments (S3). (D) SMCT1
staining was absent from proximal tubular segments positive for CD98 (S1) but was present in CD98-negative segments (S3). A faint signal was visible in some S2
segments. G, glomerulum; S1 and S2, early and late convoluted proximal tubule, respectively; S3, straight part of the proximal tubule.
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affinity-purified and its specificity was confirmed using HRPE
cells expressing the cloned transporters (data not shown).
Positive immunofluorescence was obtained in cells expressing
both human and mouse SMCT2, indicating that the antibody
can interact with SMCT2 of both species. HRPE cells, which do
not express SMCT2 endogenously, did not yield immunoposi-
tive signal when transfected with empty vector or human
SMCT1 cDNA, confirming the specificity of the anti-SMCT2
antibody. To determine the exact localization of SMCT2 and
SMCT1 in mouse kidney, double-labeling experiments were
performed with antibodies against the 4F2hc (CD98) which is
localized exclusively to the basolateral membrane of the early
proximal tubule [21]. Staining for SMCT2 and SMCT1 (red)
was visible in the cortical region of the kidney consistent with
their expression in the proximal tubule (Fig. 5). There were no
immunopositive signals when the antibody was neutralized with
the antigenic peptide before use (data not shown), attesting to
the specificity of the antibody. The signals for SMCT2 or
SMCT1 did not overlap with those of CD98, demonstrating that
both transporters are localized to the brush border membrane
(Fig. 5A–D). Importantly, SMCT2 and SMCT1 showed a
differential expression along the proximal tubule. SMCT2 was
broadly expressed with the staining extending from the
glomerulum, over the convoluted tubule (S1 and S2 segments)
to the late proximal tubule (S3 segment). In contrast, SMCT1staining was predominantly confined to tubular regions which
had no CD98 signal, suggesting that SMCT1 expression is
largely restricted to the late proximal tubule (straight proximal
tubule, S3 segment). However, a faint signal for SMCT1
expression was visible in S2 segment of some nephrons.
4. Discussion
The studies presented here describe for the first time the
functional features of human SMCT2. The cloned human SMCT2
functions as a Na+-coupled transporter for lactate and other
monocarboxylates such as pyruvate, butyrate, and nicotinate. The
substrate affinity of the transporter is much lower than that
reported for human SMCT1 but similar to those described for the
low-affinity Na+-coupled lactate transport system in apical
membrane vesicles from pars convoluta [6]. The immunolocali-
zation of the transporter in mouse kidney agrees with the location
of the low-affinity transport system. SMCT2 is expressed in the
apical membrane of proximal convoluted tubule.
It is not clear at present whether the transport process
mediated by human SMCT2 is electrogenic or not. The
cooperativity of Na+ activation of SMCT2 transport function
is not robust as evident from the shallow nature of the sigmoidal
relationship between Na+ concentration and transport activity.
Though a value of N1 for Hill coefficient suggests that the
transport process may be electrogenic, substrate-induced inward
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(b5 nA) (data not shown). Mouse SMCT2 also induced only
small inward currents (∼10 nA) under similar conditions [15].
Recently, Plata et al. [22] reported on the cloning and
characterization of the zebrafish orthologs of SLC5A8 and
SLC5A12. In their studies, they have conclusively demonstrat-
ed that SLC5A8 is an electrogenic transport system and
SLC5A12 is an electroneutral transport system. Therefore, it
is quite possible that mammalian SMCT2, similar to its ortholog
in zebrafish, is an electroneutral transport system. The small
magnitude of the currents observed with human SMCT2 and
mouse SMCT2 suggests that these currents may not be directly
coupled to solute transport.
The immunofluorescence studies with mouse kidney sections
show that the low-affinity (SMCT2) and high-affinity (SMCT1)
lactate transporters are present in the apical membrane. The
expression of SMCT2 is evident all through the entire length of
the proximal tubule (S1/S2/ S3 segments) whereas the expression
of SMCT1 is mostly restricted to the straight portions of the
proximal tubule (S3 segment). Though the anti-SMCT2 antibody
was able to interact with human SMCT2 in transfected cells, our
attempts to use the antibody to localize SMCT2 in human kidney
sections resulted in high nonspecific staining. We believe that the
distribution for SMCT2 and SMCT1 in human kidney would be
similar to that in mouse kidney; however, interspecies differences
have been observed with respect to the localization and
expression of transporters, e.g., organic cation transporters [23].
The differential distributions of high-affinity and low-affinity
lactate transporters in various segments of the proximal tubule are
similar to what has been reported for the high-affinity and low-
affinity Na+-dependent transporters for glucose [24] and H+-
dependent transporters for peptides [25]. This expression pattern
of SMCT2 and SMCT1 in the proximal tubule has physiologic
significance in terms of lactate reabsorption in the kidney. The
concentration of lactate is quite high, equal to the concentration
found in plasma, in the lumen of the early parts of the proximal
convoluted tubule. SMCT2 is expressed in this region. This
transporter, being a low-affinity type, would be able to mediate
the reabsorption of lactate very effectively under these conditions.
As lactate reabsorption progresses via SMCT2, the luminal
concentration of lactate would fall along the proximal tubule.
SMCT1 is expressed in the straight portions of the proximal
tubule. This transporter, being a high-affinity type, would be able
to carry out the reabsorption process effectively under these
conditions. Thus, the two transporters couldwork in tandem in the
proximal tubule, contributing to the efficient reabsorption of
lactate.
We believe that SMCT1 and SMCT2 are the only transporters
that are responsible for the transfer of lactate from the tubular
lumen into the cells across the apical membrane in the proximal
tubule. Recently, we reported that the expression of both these
transporters is almost completely abolished in a mouse model in
which the gene coding for the transcription factor c/ebpδ had been
disrupted [16]. In this mouse model, the urinary excretion of
lactate is markedly increased, with consequent decrease in plasma
levels of lactate compared to wild typemice. The plasma levels of
lactate in c/ebpδ null mice are only about 5% of control values.These findings with c/ebpδ null mice provide convincing in vivo
evidence for the obligatory role of SMCT1 and SMCT2 in lactate
reabsorption in the kidney.
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